Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
Objectives To evaluate the extent to which patients with type 2 diabetes discontinue metformin therapy when initiating second-line treatment and factors associated with metformin discontinuation, using baseline data from the DISCOVER study programme.Design DISCOVER is a 3-year, prospective, observat...
Saved in:
| Main Authors: | Peter Fenici, Niklas Hammar, Linong Ji, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Wolfgang Rathmann, Iichiro Shimomura, Marilia B Gomes, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Hungta Chen, Javier Cid-Ruzafa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/8/e034613.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
by: Jesús Medina, et al.
Published: (2021-03-01) -
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
by: Jesús Medina, et al.
Published: (2019-05-01) -
The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation
by: Tomoya Mita, et al.
Published: (2017-01-01) -
Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data
by: Jumpei Ito, et al.
Published: (2025-04-01) -
One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)